Latest Headlines

Latest Headlines

Sanofi's Praluent scores first place in line for UnitedHealth unit's PCSK9 patients

Here's one way to privilege a new drug over its rival without blocking one entirely: Make patients try your favored product first. That's what UnitedHealth's Oxford unit is doing with the two new cholesterol-fighting PCSK9 drugs,  Bloomberg  reports, citing a policy update. 

Amgen slaps $178K price on rare new leukemia drug Blincyto

Amgen's leukemia drug Blincyto, FDA-approved late last year to treat an uncommon form of the disease, made its debut at a list price of $178,000 per patient. Though not the priciest rare-disease treatment, it was the most expensive cancer drug at the time, the latest in a new round of expensive treatments, each of which seems to top the last.

Amgen nabs Kyprolis OK in Europe as U.S. competition mounts

Amgen's multiple myeloma treatment Kyprolis finally won approval in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time.

Amgen looks to Europe for Kyprolis boost as it battles Pomalyst, Darzalex at home

It's been more than three years since Amgen's multiple myeloma treatment Kyprolis won approval from U.S. regulators. Now, it's finally done the same in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time for the California biotech.

Amgen nabs another PCSK9 exclusive, this time with giant CVS

Amgen's PCSK9 med Repatha and Sanofi and Regeneron's competitor Praluent may have both nabbed coverage from top PBM Express Scripts. But now, Amgen has inked an exclusive pact with the giant's archrival, CVS.

Amgen's Repatha scores an exclusive with CVS

In the jockeying for share in the brand-new market for the specialized PCSK9 cholesterol-lowering meds, Amgen has picked up an edge over Sanofi by nailing a formulary exclusive with CVS. To get that preferred spot, Amgen has again agreed to tie the price of the drug to its effectiveness.

Samsung and Biogen verge on EU approval with an Enbrel biosimilar

Samsung Bioepis is months away from winning European clearance to market a copy of Amgen and Pfizer's blockbuster rheumatoid arthritis treatment Enbrel, securing a positive recommendation from EU regulators.

U.K. cost gatekeeper says 'no' to Amgen's PCSK9 cholesterol fighter Repatha

Amgen got a thumbs-down from U.K. cost watchdog the National Institute for Health and Care Excellence (NICE) for its PCSK9 cholesterol-fighter Repatha (evolocumab), bad news for the drug as it contends with pricing pushback and competes head-to-head with Sanofi and Regeneron's Praluent for market share.

Novartis takes a third biosimilar shot at Amgen with a copy of the blockbuster Neulasta

Novartis is moving toward the U.S. market with a biosimilar of Amgen's Neulasta, awaiting FDA approval for a long-acting treatment designed to boost white blood cell count.

Activist investor's new advice for Amgen: Merge with Allergan

Dan Loeb, the activist investor who once called for Amgen to break itself in two, is now advising the Big Biotech to consider merging with Allergan, according to Bloomberg.